Literature DB >> 34116042

Effect of anti-hyperglycemic drugs on endoplasmic reticulum (ER) stress in human coronary artery endothelial cells.

Poonam Kapadia1, Priyanka Bikkina1, Marie Angelica Landicho1, Shrina Parekh1, Michael J Haas2, Arshag D Mooradian1.   

Abstract

Endoplasmic reticulum (ER) stress plays a critical role in progression of diabetes and development of complications, notably cardiovascular disease. Some of the contemporary anti-hyperglycemic drugs have been shown to inhibit ER stress. To extend these observations, the effects of various anti-hyperglycemic agents were screened for their effects on ER stress. Seven classes of anti-hyperglycemic drugs were screened including sulfonylureas, meglitinides, metformin, α glucosidase inhibitors, thiazolidinedione, glucagon like peptide 1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT-2) inhibitors. ER stress was measured in human coronary artery endothelial cells (HCAEC) either treated with tunicamycin (TM) or cultured in hyperglycemic conditions (27.5 mM dextrose). The ER stress was measured with the secreted alkaline phosphatase (ES-TRAP) assay. Mediators of the unfolded protein response, including activating transcription factor 6 (ATF6), glucose-regulated protein 78 (GRP78), phospho-inositol-requiring enzyme 1α (pIRE1α), IRE1α, phospho-protein kinase R (PKR)-like endoplasmic reticulum kinase (pPERK), and PERK were measured by Western blot. Metformin, GLP-1 receptor agonists (GLP-1, exendin 4, liraglutide, albiglutide, and lixisenatide) and SGLT-2 inhibitors (canagliflozin, dapagliflozin, and empagliflozin) were the only anti-hyperglycemic drugs screened that reduced ER stress caused by pharmacological (tunicamycin) or hyperglycemic conditions. High-dextrose and TM increased IRE1α and PERK phosphorylation and ATF6 and GRP78 expression, while treatment with metformin, liraglutide (a GLP-1 receptor agonist) and dapagliflozin (a SGLT-2 inhibitor), suppressed IRE1α and PERK phosphorylation as well as ATF6 and GRP78 expression. Thus, the cardioprotective effects of metformin, some of the GLP-1 receptor agonists and SGLT2 inhibitors may be partly related to their ability to reduce ER stress.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  GLP-1 Agonist; HCAEC; Unfolded protein response

Mesh:

Substances:

Year:  2021        PMID: 34116042     DOI: 10.1016/j.ejphar.2021.174249

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

Review 1.  Soluble Epoxide Hydrolase and Diabetes Complications.

Authors:  Natasha Z Anita; Walter Swardfager
Journal:  Int J Mol Sci       Date:  2022-06-02       Impact factor: 6.208

Review 2.  Metformin in cardiovascular diabetology: a focused review of its impact on endothelial function.

Authors:  Yu Ding; Yongwen Zhou; Ping Ling; Xiaojun Feng; Sihui Luo; Xueying Zheng; Peter J Little; Suowen Xu; Jianping Weng
Journal:  Theranostics       Date:  2021-09-09       Impact factor: 11.556

Review 3.  GLP-1 Receptor Agonists and Coronary Arteries: From Mechanisms to Events.

Authors:  Aurélie Pahud de Mortanges; Eldem Sinaci; Dante Salvador; Lia Bally; Taulant Muka; Matthias Wilhelm; Arjola Bano
Journal:  Front Pharmacol       Date:  2022-03-08       Impact factor: 5.810

4.  Pitavastatin protects against neomycin-induced ototoxicity through inhibition of endoplasmic reticulum stress.

Authors:  Yunhao Wu; Wei Meng; Ming Guan; Xiaolong Zhao; Chen Zhang; Qiaojun Fang; Yuhua Zhang; Zihui Sun; Mingjing Cai; Dongdong Huang; Xuechun Yang; Yafeng Yu; Yong Cui; Shuangba He; Renjie Chai
Journal:  Front Mol Neurosci       Date:  2022-08-03       Impact factor: 6.261

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.